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ABSTRACT 
Neuroendocrine abnormalities are common in Parkinson’s disease (PD) and include 
disruption of melatonin secretion, disturbances of glucose, insulin resistance and 
bone metabolism, and body weight changes. They have been associated with 
multiple non-motor symptoms in PD and have important clinical consequences, 
including therapeutics. Some of the underlying mechanisms have been implicated in 
the pathogenesis of PD and represent promising targets for the development of 
disease biomarkers and neuroprotective therapies.  
In this systems-based review we describe clinically relevant neuroendocrine 
abnormalities in Parkinson’s disease to highlight their role in overall phenotype. We 
discuss pathophysiological mechanisms, clinical implications, and pharmacological 
and non-pharmacological interventions based on the current evidence. We also 
review recent advances in the field, focusing on the potential targets for development 
of neuroprotective drugs in Parkinson’s disease and suggest future areas for 
research.     
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INTRODUCTION 
Parkinson’s disease (PD) is a common neurodegenerative condition characterised by 
both motor and non-motor symptoms (NMS). Whilst the classic motor features are 
attributable to nigrostriatal dopaminergic cell loss, the spectrum of NMS reflects a 
more complex aetiology including neuroendocrine and metabolic abnormalities.  
Neuroendocrine abnormalities in PD are important for several reasons. They are 
common, mainly recognised and studied in advanced stages of PD, and associated 
with multiple NMS.1 However, they appear to be an integral feature of PD at all 
stages of disease, not secondary to disruption of other physiological processes or 
side effects from medication. Recent advances have shed light on the underlying 
pathophysiology and relationship to PD, although important questions remain 
regarding the effect of neurodegeneration on neuroendocrine axes. A better 
appreciation of the neuroendocrine abnormalities in PD and their clinical implications 
may allow tailored clinical assessments and offer better symptomatic therapeutic 
interventions. In addition, neuropeptides and hormones are easy to assay in various 
body fluids (blood/urine/saliva). Altered concentrations may correlate with disease 
severity and play a role in disease progression and pathogenesis. As such, they 
represent potential biomarkers of disease state. Finally, neuroendocrine 
abnormalities could form the basis for the future development of targeted therapies 
for NMS and neuroprotective treatments in PD.  
This review does not cover every endocrine system or metabolic abnormality 
reported to be disrupted in PD, but provides a systems-based overview of those 
where there have been recent advances in terms of the clinical or therapeutic 
implications. We discuss the current epidemiological and pathophysiological 
evidence available, future areas for research, and give therapeutic recommendations 
for each of these neuroendocrine and metabolic disorders in PD.    
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SEARCH STRATEGY 
A Pubmed/Medline search was performed for articles published in English between 
January 1990-June 2016. We combined searches using ‘Parkinson’s disease’ and 
the keywords ‘neuroendocrine’, ‘circadian disorder’, ‘suprachiasmatic nucleus’, 
‘hypothalamus’, ‘melatonin’, ‘pineal gland’, ‘diabetes’, ‘insulin resistance’, ‘glucose 
intolerance’, ‘body weight’, ‘feeding behaviour’, ‘leptin’, ‘ghrelin’, ‘osteoporosis’, ‘bone 
mineral density’ and ‘vitamin D’. Reference lists were manually checked to capture 
any additional articles. The final list of references was generated based on the 
relevance of the articles to the aim of this review.    
 
CIRCADIAN RHYTHM AND SLEEP DISORDERS 
Circadian (daily) rhythms are present in almost all physiological systems of the 
human body,  the sleep-wake cycle being most apparent. The system responsible for 
this near 24-hour rhythm is composed of a central pacemaker and peripheral 
oscillators (Figure 1). The central biological master clock is located in the 
suprachiasmatic nucleus (SCN) of the anterior hypothalamus2  and its rhythmic 
activity is the result of the expression of clock genes. The SCN is entrained to the 24 
hour environmental light cycle through the retino-hypothalamic tract, circulating 
melatonin, and time cues from peripheral oscilators. Melatonin is the most important 
endogenous entraining agent and its production by the pineal gland during darkness 
is regulated by the SCN.3  
Coordination of circadian rhythms is an essential element of optimal physical and 
mental health4  and its disruption has been associated with metabolic disturbances,5 
disorders of the immune system,6 increased cancer risk,7 renal dysfunction,8 
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cardiovascular disease,9 impaired cognition,9 psychiatric and mood disorders.10 11 
Growing evidence suggests that alterations of the circadian system in PD patients 
might contribute not only to sleep-wake cycle dysregulation but also to other NMS.   
 
Pathophysiology and abnormalities in PD 
Clinical circadian abnormalities  
- Motor function: Actigraphic studies have demonstrated disruption of the 
physiological motor pattern, with PD patients displaying increased activity at 
bedtime and reduced activity levels during the day which correlates with 
disease stage.12 13 Moreover, PD patients exhibit worsening of their motor 
symptoms with diminished motor response to levodopa therapy in the 
evening unexplained by pharmacokinetic factors14 15 which may reflect 
disruption of circadian regulation of dopaminergic systems.16  
- Non-motor function: Cardiovascular circadian rhythms are also disrupted in 
PD, with reduced heart rate variability12 17 18 and reversal of the circadian 
blood pressure profile with nocturnal hypertension.19 20 A lower core body 
temperature and reduced nocturnal fall in body temperature have also been 
reported, suggesting a circadian disruption of thermoregulation.21 PD patients 
also show circadian fluctuations of visual performance measured by contrast 
sensitivity, 22 linked to altered diurnal fluctuations in retinal dopamine. 23 
Although other elements including autonomic dysfunction and the effect of 
medication are likely to have an impact, these studies have demonstrated 
disrupted circadian rhythms contributing to these abnormalities.   
- Sleep: Sleep disorders in PD  are very common and include sleep 
fragmentation, insomnia, REM sleep behaviour disorder (RBD), restless legs 
syndrome and excessive daytime sleepiness.24 They have a multifactorial 
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origin including re-emergence of motor and NMS at night, nocturia, side 
effects of dopaminergic and other medications, and alterations in the 
circadian regulation of the sleep-wake cycle. Sleep disturbances in PD have 
been correlated with increased α-synuclein load and neurodegeneration of 
brain regions involved in promoting sleep such as the lower brainstem (locus 
coeruleus, raphe nuclei), amygdala, thalamus and hypothalamic 
(paramammillary and posterior nuclei). 25 The wake-promoting effect of the 
orexin system of the lateral hypothalamus has also been implicated in the 
pathogenesis of sleep disturbances in PD. CSF orexin levels in PD have 
shown conflicting results depending on CSF sampling site (ventricular vs 
lumbar) and stage of the disease,26-28 but well-designed pathological studies 
showed a severe reduction of orexin neurons in the lateral hypothalamus 
correlating with disease severity.29 30 In addition to these neuroanatomical 
structures, disruption to the molecular elements of the circadian system (see 
below) are believed to contribute to sleep disorders in PD.  
- PD pathophysiology: Study of animal models has suggested that alterations 
in the circadian system might accelerate the pathological processes 
underlying PD.31  
 
Functional circadian abnormalities  
- Clock genes: At a molecular level, circadian rhythms are regulated by several 
clock genes forming a set of interlocking transcription-translation feedback 
loops. Their pattern of expression has been proposed as a peripheral marker 
of circadian activity.32 Abnormalities  of clock genes in peripheral blood of PD 
patients include altered expression of Bmal1, 33 34 Bmal2,35 and altered 
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promoter methylation of Npas2.36 However, the clinical implications 
associated with these changes are unclear.   
- Melatonin: As there is no pineal storage of melatonin, circulating 
concentrations are considered a good biological marker of the circadian 
system.3 Early studies showed a phase advance of the nocturnal melatonin 
secretion, and decrease in night-to-daytime ratio of melatonin secretion which 
probably reflects dopaminergic treatment.37 38 More recent studies, with 
careful design to control the effects of exogenous variables, showed 
diminished amplitude of serum melatonin secretion in PD patients on 
dopaminergic therapies, which correlated with excessive daytime sleepiness39 
and various alterations in sleep architecture.34 . In contrast, an increase in 
salivary melatonin was found in treated, but not in unmedicated PD patients 
or controls.40 Differences in experimental protocols (particularly sample type, 
sample collection timing and control of exogenous factors) makes comparison 
between these studies challenging.  
- Cortisol. The secretory rhythm of cortisol is a sensitive marker of circadian 
function and persistently elevated concentrations of cortisol in blood 34 41 and 
saliva 42 have been reported in PD patients. However, whilst the recognised  
effect of exogenous stress on cortisol concentrations makes interpretation 
difficult, impulse control behaviours,42 weight changes after deep brain 
stimulation (DBS)43 and mood disturbances44 have all been associated with 
cortisol secretion abnormalities in PD patients.  
These preliminary data suggest that circadian rhythm disruption is an early feature of 
PD as these abnormalities were found in newly diagnosed patients34 although the 
neuroanatomical site of disruption remains unclear. A recent study showed a 
reduction in hypothalamic grey matter volume (measured using magnetic resonance 
imaging) in PD patients compared to controls, together with a linear correlation 
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between hypothalamic volume and 24-hour melatonin output in the PD group.45 
Since melatonin is produced by the pineal gland under circadian control, collectively 
these results suggest that degenerative changes in neural structures controlling 
pineal output (such as the SCN) may be responsible for reduced melatonin output in 
PD. Further study of neuroanatomical components regulating  the circadian system 
(e.g the pineal gland) should be performed  in PD. 
 
Therapeutic implications  
- Melatonin. Dowling et al 46 compared the administration of melatonin 5 or 50 
mg/day versus placebo for a period of two weeks in a randomised controlled 
cross-over trial of 40 PD patients with sleep disturbances. Actigraphy showed 
a minimal increase in total night-time sleep (10 minutes) in the high dose 
group, but only subjective improvement in sleep quality in the lower dose 
group, compared with placebo. Another study with 18 PD patients 
randomised to melatonin 3 mg/day or placebo for four weeks showed 
significant improvement in subjective quality of sleep in the melatonin group 
but no significant differences on polysomnography.47 Based on these 
results,48 a consensus from the Movement Disorder Society concluded that 
there was insufficient evidence to recommend the routine use of melatonin for 
the treatment of insomnia in PD.49 Further studies with large samples, longer 
duration, careful protocol design to control exogenous factors and 
identification of patient subgroups where sleep abnormalities are likely to be 
secondary to circadian dysfunction are warranted.  
- Bright light therapy (BLT): It has been postulated that BLT might restore 
circadian rhythmicity in PD, as it has demonstrated efficacy in the treatment 
of mood disorders.50 Although  promising results have been reported on its 
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effect on sleep, mood and motor function in PD patients,51 BLT has only been 
assessed in a few studies with different light therapy regimes and 
assessment protocols, making it difficult to draw firm conclusions. The only 
randomised placebo-controlled trial of 18 PD patients treated with BLT 
showed improvement of  mood disturbances, parts I, II and IV of the Unified 
Parkinson’s Disease Rating Scale (UPDRS) in comparison to the placebo 
group, but failed to improve motor UPDRS or sleep.52 Other cases series 53 
and retrospective open label studies 54 have shown additional improvement of 
sleep and motor function. Further studies with standardized protocols and 
rigorous design are required to validate these results.    
 
Key points 
 Studies of PD patients have shown evidence for disruption of circadian 
rhythms in motor and non-motor activities, and of markers of circadian activity 
(clock genes, melatonin, cortisol) in PD patients. 
 This is likely to reflect disruption of the circadian system at many levels 
including the activity of the SCN and its humoral outcome signal melatonin. 
 Although melatonin and BLT could be potential treatment options for these 
circadian disruptions, further evidence is needed to justify their use 
 
DIABETES AND GLUCOSE METABOLISM  
The potential association between PD and type 2 diabetes (T2DM) has long been 
recognised,55 and has been the subject of increased research attention  in recent 
years.56  
 
 11 
 
Epidemiology 
The prevalence of glucose intolerance has been estimated to be as high as 80% in 
PD patients in historical studies,55 although more recent epidemiological data are 
conflicting.  A recent meta-analysis of case-control studies reported a negative 
association (OR = 0.75 [95%CI 0.58-0.98])57 although still observed that 2.9% of PD 
patients had a diagnosis of diabetes compared to only 1.6% of non-PD population. 
Case-control studies are potentially prone to selection bias towards individuals 
attending specialist clinics, and cannot account for subsequent development of either 
PD or diabetes, making findings of association tentative. Indeed these results 
contrast with a meta-analysis of prospective studies, in which pre-existing T2DM was  
found to be a risk factor for future PD (RR = 1.26 [95%CI 1.03-1.55]; p <0.0001).58 59 
Conflicting results might  be explained by heterogeneity between studies, differing 
case ascertainment of both conditions,  the potential for misdiagnosis, and  failure to 
take into  account for the modulating effect of diabetes medications on disease 
expression. Environmental and ethnic factors might also affect the association in 
different populations.  
T2DM might also exert a modifying effect on PD phenotype and disease progression. 
A case-control study showed that PD patients with antecedent diabetes had more 
severe motor symptoms, higher scores on the motor UPDRS, and required higher 
doses of levodopa.60 Clinical studies have shown that the presence of T2DM is 
associated with specific phenotypes, including greater postural instability, gait 
difficulties and cognitive impairment.61-63 This association is clinically relevant since 
axial motor symptoms and cognitive impairment are less responsive to dopaminergic 
therapies and are a major cause of disability. The lack of therapeutic response might 
be secondary to non-dopaminergic neurotransmitter involvement, as the phenotypic 
variability was not explained by differences in nigrostriatal dopaminergic denervation 
on [11C]dihydrotetrabenazine PET scans in PD patients with and without T2DM.61        
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Pathophysiology and abnormalities in PD 
Recent studies have provided potential mechanisms by which T2DM could be a risk 
or modifying factor for PD:  
- Cerebrovascular disease: Increased prevalence of vascular pathology and 
vascular parkinsonism in patients with T2DM might account for these 
findings. However, epidemiological association between PD and T2DM 
remained significant after adjustment for vascular risk factors and exclusion of 
participants with clinical cerebrovascular disease.58 59 MRI studies of the 
presence of cerebrovascular disease and leukoaraiosis showed no 
differences between groups of PD patients with or without diabetes.61  
- Dopaminergic medication: The effect of some anti-PD medications on 
glucose metabolism has been suggested as a potential confounding factor, 
since evidence suggests a reciprocal regulation between insulin and brain 
dopaminergic activity.64 Chronic treatment with levodopa has been shown to 
induce decreased glucose tolerance, hyperglycaemia and 
hyperinsulinaemia.65 66 On the other hand, bromocriptine increases insulin 
sensitivity, improves glycaemic control, and is licensed for the treatment of 
diabetes.67 However, reduced insulin-mediated glucose uptake,65 and 
inhibition of early insulin secretion and long term hyperinsulinaemia and 
hyperglycaemia after glucose loading68 have also been found in samples of 
drug-naïve patients, supporting the hypothesis that abnormal insulin 
signalling and glucose metabolism predate dopaminergic treatment in PD 
patients.  
- Cellular and molecular biology: It has been hypothesised that aberrant insulin 
signalling might ultimately lead to insulin resistance and diabetes, and put 
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individuals at increased risk for PD.56 69 Mitochondrial dysfunction, 
neuroinflammation, increased endoplasmic reticulum stress, abnormal protein 
aggregation and metabolic abnormalities are common to both diabetes and 
PD, suggesting a pathophysiological link.56 69  
 
Therapeutic implications 
The common pathophysiological mechanisms shared by T2DM and PD may lead to 
more effective treatments which target both conditions. A prospective observational 
study showed that treatment using a combination of metformin and a sulfonylurea 
appeared to have a protective effect on the risk of developing PD in a Taiwanese 
cohort of diabetic patients.70 Special attention has focussed on the potential 
neuroprotective properties of peroxisome proliferator activated receptor gamma 
(PPAR-γ) and its coactivator 1-α (PGC1α) due to its pivotal role in mitochondrial 
respiration and gluconeogenesis. The thiazolidinediones, (such as pioglitazone and 
rosiglitazone) are a class of PPAR-γ agonist. They have been successfully tested for 
their neuroprotective potential in animal models of PD.71 The potential therapeutic 
effect of these drugs on PD was further supported by a retrospective cohort study 
which showed a 28% lower rate of developing PD in those diabetic patients treated 
with thiazolidinediones compared to other anti-diabetic drugs.72 These results 
prompted a large, multicentre, double-blind, placebo-controlled trial including 210 
patients randomly assigned to 45mg/day pioglitazone, 15mg/day pioglitazone or 
placebo to assess the potential effect on PD patients. Results failed to show a 
significant benefit on symptoms (measured using total UPDRS) and the authors 
concluded that pioglitazone was unlikely to modify clinical progression in PD at the 
doses studied.73  
 14 
 
More promising are the preliminary clinical results for exenatide, a synthetic  
glucagon-like peptide 1 (GLP1) receptor agonist licensed for the treatment of 
diabetes, which has been evaluated as a neuroprotective agent in patients with PD 
(for a detailed description of  PD pathogenesis and GLP1 receptor stimulation, see 
review by Athauda and Foltynie).74 An initial open label randomised controlled trial 
comparing 20 PD patients treated with exenatide and 24 PD patients acting as 
controls showed a clinically relevant improvement in motor (5.6 points on part 3 
UPDRS) and cognitive (5.3 points on Mattis Dementia Rating Scale) domains in the 
treatment group after 12 months.75 Further studies with larger samples are currently 
on going (ClinicalTrials.gov number NCT01971242).  
 
Key points 
 Pre-existing T2DM appears to be a risk factor for PD and to modify its clinical 
course with more severe disease progression, axial motor symptoms and 
cognitive impairment. 
 The pathophysiological link is not well understood but it may involve 
mitochondrial dysfunction, neuroinflammation, increased oxidative stress, 
abnormal protein aggregation and metabolic abnormalities 
 Due to shared pathophysiology, several antidiabetic drugs are being explored 
as potential treatment for PD with promising initial results in the case of 
exenatide. 
 
BODY WEIGHT AND ENERGY METABOLISM 
Extensive research on the mechanisms governing body weight, feeding behaviour 
and energy metabolism has provided insight into complex interactions between 
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peripheral signals and the central nervous system. The classic concept of 
anatomically distinct ‘satiety/feeding’ centres has been gradually replaced by a more 
complex network of interconnected neurons of homeostatic and hedonic systems, 
receiving and integrating multiple orexigenic and anorexigenic signals from 
peripheral tissues, nutrients and other areas of the central nervous system (Figure 
2).76-78  
The hypothalamus is the central component of the homeostatic control of feeding 
behaviour with anorexigenic and orexigenic cells: the infundibular nucleus produces 
cocaine and amphetamine regulated transcript (CART) and melanocyte stimulating 
hormone (MSH) with anorexigenic activity, while the orexigenic cells are located in 
the infundibulum via neuropeptide Y (NPY) and Agouti related protein (AgRP) 
neurons  and lateral hypothalamic area (orexin and melanin-concentrating hormone - 
MCH). The activity of hypothalamic neurons is influenced by peripheral humoral 
signals with opposite functions including leptin, ghrelin, gut satiety peptides and also 
levels of insulin, glucose or fatty acids. Leptin is an adipokine synthesized by fat 
tissue reflecting the energy reserve and produces anorexigenic effects, whereas 
ghrelin, a peptide synthesized by the gastric mucosa during fasting, promotes 
feeding, weight gain and stimulates growth hormone secretion. The hedonic control 
(sensorial information, food reward systems) is integrated in several areas including 
the mesolimbic dopaminergic system, insular cortex, dorsal striatum, and anterior 
cingulate and orbitofrontal cortices.  
 
Epidemiology 
The mechanisms regulating food intake might be implicated in other behaviours and 
brain functions including learning and memory, and the positive association between 
obesity, brain atrophy and dementia is recognized.79 A causal relationship between 
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being overweight and PD is more controversial and results from prospective 
epidemiological studies are inconclusive.80 Some have shown a positive association 
of indices of obesity (body mass index (BMI) 81-83 and triceps skinfold thickness84) 
with an increased risk of PD, although these results have not been reproduced in 
other cohorts.85 86  
On the other hand, the inverse association is well recognized and unintentional 
weight loss has been consistently reported with PD (affecting approximately 50% of 
patients).82 87-89 A meta-analysis including 871 patients showed an overall reduction 
of 1.73kg/m2 in patients with PD compared with controls, with a positive association 
with disease severity but not with disease duration.90 This weight loss carries 
important clinical implications and appears to be associated with a more rapid 
disease progression91 and to correlate inversely with health-related quality of life.92 
 
Pathophysiology and abnormalities in PD 
PD intrinsic factors 
- Dopaminergic dysfunction: Due to the role of dopamine in the regulation of 
the hedonic mechanisms of feeding behaviour,93 dopamine dysfunction 
producing anorexigenic signals in the hypothalamus has been proposed to 
contribute to weight loss in PD.  
- Levodopa: Despite the fact that weight loss has been shown to be more 
prominent after commencing levodopa treatment in observational studies,94 95 
it seems that the levodopa requirement simply reflects disease severity. In 
addition, weight loss in PD has been reported before treatment with 
dopaminergic therapies,96 sometimes predating the onset of motor 
symptoms.88  
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- Energy expenditure/intake imbalance: Reduced caloric intake secondary to 
motor (rigidity, impaired hand coordination) and gastrointestinal (dysphagia, 
reduced bowel motility, upper gastrointestinal symptoms) complications have 
been proposed as a factor driving the energy imbalance contributing to weight 
loss in PD. However, several studies have demonstrated that weight loss 
occurs despite an increased energy intake in patients with PD.88 96 Given the 
correlation between weight loss and disease severity,90 97 motor symptoms 
(tremor, rigidity) and motor complications (dyskinesias) could potentially 
increase the energy expenditure at rest resulting in weight loss.98 However, 
other studies have demonstrated that the total daily energy expenditure is not 
higher in PD patients with weight loss compared to PD patients without 
weight loss99 and healthy controls,100 arguing against the possibility that 
abnormally elevated energy expenditure contributes to weight loss in PD. 
Overall it seems that the weight loss in PD is not explained by an energy 
imbalance, and can occur despite an increase in caloric intake.   
 
Peripheral mechanisms of feeding behaviour regulation 
- Leptin: Measurement of leptin97 101 and other adipokines102 have shown no  
significant differences between  PD patients with and without weight loss, and 
controls. Despite results showing a trend towards reduced concentration in 
PD patients, this correlates with BMI and is likely that reduced leptin 
concentration reflects reduced body fat tissue content rather than being a 
causal factor for weight loss.  
- Ghrelin: Ghrelin levels rise with prolonged fasting and fall rapidly after food 
ingestion, with an overall negative correlation with body weight. In PD 
patients, however, there is a lower plasma ghrelin concentration in those 
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patients with lower BMI103 and a reduction in the levels of ghrelin after the 
postprandial fall in PD patients and idiopathic RBD,104 suggesting 
dysregulation of its secretion. Since RBD is considered a potential pre-motor 
stage of PD, ghrelin has been proposed as a potential peripheral biomarker 
for early PD.104 Recent studies demonstrated that ghrelin exerts a number of 
roles in other extra-hypothalamic tissues including activation of the 
dopaminergic nigrostriatal system, hippocampus and mesolimbic 
dopaminergic system, and is implicated in learning and memory, reward 
behaviour, motivation, anxiety and depression.105  More importantly, ghrelin is 
reported to have neuroprotective properties in the nigrostriatal system in 
experimental animal models of PD106 mediated by the same mitochondrial 
function regulator (PGC1α)107 suggested as a potential therapeutic target in 
neuroprotection for PD and T2DM56 . Although these findings need to be 
replicated in humans, ghrelin appears a possible therapeutic target for 
disease neuroprotection, as well as treatment target for of NMS such as 
obesity, apathy and depression. 
 
Central mechanisms of feeding behaviour regulation 
- Deep brain stimulation: The role of the central regulatory hypothalamic 
mechanisms in weight disturbance in PD has recently attracted much 
attention in part due to the effects of DBS on body weight. Rapid weight gain 
has been consistently reported in multiple studies of PD patients after 
subthalamic nucleus (STN) DBS. This greatly exceeds the weight loss seen 
in medically treated patients.108-111 These effects are not observed in patients 
with essential tremor undergoing DBS of the motor thalamus.112 Various 
mechanisms have been postulated, but it seems that STN DBS may induce 
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changes in the regulatory mechanism of the hypothalamus with normalization 
of energy metabolism.113 These effects seem target dependant, being more 
marked with bilateral STN stimulation (compared to unilateral STN 
stimulation114 or globus pallidus internus (GPi) stimulation115) and with more 
medially placed electrodes in STN DBS.116 A stimulatory effect of the DBS 
electrode on fibre bundles projecting from or to the hypothalamic nuclei 
involved in the regulation of feeding behaviour and metabolism is a plausible 
hypothesis, although a recent study assessing the global function of the 
hypothalamus in PD patients after DBS did not show any abnormalities of the 
hypothalamic-adrenal, hypothalamic-gonadal or hypothalamic-somatotropic 
axes.44 In PD patients with STN DBS, despite high leptin concentrations 
secondary to the weight gain, one study reported  an increase of the 
orexigenic neuropeptide Y117 118 and hypothesized that DBS might make the 
hypothalamic neurons of the infundibular nucleus resistant to the 
anorexigenic effect of leptin. Normalization of cortisol levels in PD has also 
been reported after DBS 44 118 119 and its anabolic effect has been suggested 
as responsible for weight gain. 43   
- Hypothalamic histopathological changes: Neuronal populations in the lateral 
hypothalamic area (orexin and MCH neurons) are inhibited by leptin, 
activated by ghrelin and promote feeding (Figure 2). As described previously, 
pathological studies have shown a severe reduction of both neuronal 
populations in PD patients correlated with disease severity.29 30 A recent study 
also demonstrated the presence of Lewy body pathology involving the 
infundibular nucleus even at preclinical stages and these pathological 
changes increased with clinical progression.120 However Lewy pathology did 
not show a correlation with the severity of weight loss suggesting that 
hypothalamic functional deficits rather than classical PD pathological changes 
may be responsible for the weight fluctuations.   
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- Hedonic system: Dysregulation of the dopaminergic mechanisms of hedonic 
control of feeding behaviour might also contribute to weight changes in PD. 
Although dopaminergic medications are generally reduced following STN 
DBS surgery, eating disorders secondary to behavioural changes following 
DBS may occur due to abnormalities of dopaminergic signalling similar to the 
alterations believed to be responsible for impulse control disorders.121 The 
involvement of hedonic dysregulation in weight gain in the pathogenesis of 
PD weight gain is further supported by changes in metabolism after DBS in 
some of these brain areas including the orbito-frontal and anterior cingulate 
cortices using PET imaging.122      
The mechanisms responsible for weight fluctuations in PD are far from understood 
but current evidence does not support the classic view of an energy 
intake/expenditure imbalance secondary to motor symptoms and complications of 
PD. Instead, these data suggest a disruption of hypothalamic mechanisms of feeding 
regulation with complex interactions with peripheral signals, hedonistic control 
mechanisms and other external factors (medication and DBS).     
 
Therapeutic implications 
Only a few studies have assessed nutritional interventions and there is insufficient 
evidence for specific recommendations. However, it is now well accepted that 
nutritional assessments should be part of the routine work-up of PD patients and 
dietary intervention can improve the PD-related weight abnormalities. Individualised 
dietetic advice  improves nutritional status and quality of life in malnourished PD 
patients on medical treatment123 and nutritional intervention has been shown to be 
effective in weight control in patients with PD after DBS-STN surgery.124 Due to the 
competing interaction for intestinal absorption between L-dopa and aminoacids, 
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dietary interventions focusing on protein manipulation have been suggested in PD 
patients on treatment with L-dopa and motor fluctuations. Whilst there is insufficient 
evidence to support low-protein diets, they may induce weight loss and nutritional 
deficits in the long term. Protein-redistribution interventions have shown an 
improvement in motor function with better results when carried out in early stages of 
the disease.125  
 
Key points 
 Weight loss has been consistently reported in patients with PD. Those treated 
with DBS show a rapid and excessive weight gain. 
 This weight fluctuation is not explained by an energy expenditure/intake 
imbalance secondary to PD complications. Complex disruption of central 
(mainly hypothalamic) and peripheral mechanisms of feeding regulation  may 
account for these weight fluctuations.  
 Nutritional advice is recommended in malnourished PD patients and those 
with excessive weight gain after DBS. Protein redistribution interventions may 
improve motor control in PD patients with motor fluctuations 
 
OSTEOPOROSIS AND BONE METABOLISM 
Epidemiology 
Patients with PD have an increased risk of fractures, most commonly affecting the 
hip.126 Subsequent clinical outcome tends to be poorer than the general 
population.127 A meta-analysis of nine studies showed  a combined effect of the risk 
of fracture in PD patients (odds ratio) of 2.28 (95%CI 1.83-2.83).126 Indeed, PD has 
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been found to be the strongest single comorbidity contributing to fracture risk in the 
Global Longitudinal Study of Osteoporosis in Women cohort.128  
 
Pathophysiology and abnormalities in PD 
A significant factor is the increased risk of falls inherent to PD (secondary to postural 
instability, gait freezing, orthostatic hypotension, motor fluctuations and cognitive 
impairment). In addition, PD patients have abnormalities of bone metabolism which 
also contribute to the increased risk of fractures (Figure 3). A meta-analysis 
confirmed significantly reduced bone mineral density at the femoral neck, lumbar 
spine, total hip and total body126 in PD compared with healthy controls. Using T-score 
values, the overall combined mean difference was significantly lower in PD patients  
(-1.05; 95%CI -1.26 to -0.84).126 Immobility and reduced body mass index, both 
commonly seen in PD, are risk factors for osteoporosis, but several other factors 
disrupting bone metabolism may contribute to bone loss. 
 
Role of vitamin D 
Vitamin D has a crucial role in bone metabolism and  deficiency results in bone loss 
by compensatory hyperparathyroidism. There is increased prevalence of vitamin D 
deficiency in PD patients compared to healthy controls, as high as 55% of patients in 
some studies129 130 and patients with other neurodegenerative conditions.131 This 
suggests that this is an intrinsic feature of the disease and not just secondary to 
reduced sunlight exposure. Vitamin D has important effects on brain function and its 
receptors are expressed in dopaminergic neurons of the substantia nigra.132 It has 
been hypothesized that chronic vitamin D deficiency contributes to PD 
pathogenesis.133 The potential association of these two conditions is supported by 
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the longitudinal study by Knekt and colleagues134  showing that pre-existing vitamin D 
deficiency increased the risk of developing PD in a cohort of 3173 Finnish subjects 
after adjustment for potential confounders. Patients with highest vitamin D 
concentration had a RR = 0.33; 95%CI 0.14-0.80 of developing PD in comparison to 
the patients with the lowest concentration. A possible link at the transcriptional level 
has also been suggested, though studies looking for an association between some 
vitamin D receptor polymorphisms and the risk of PD have yielded conflicting 
results.135  
 
Role of homocysteine  
Hyperhomocysteinaemia is an independent risk factor for fractures through a dual 
mechanism reducing bone mineral density and disrupting cross-linking of collagen.136 
Homocysteine has been shown to be elevated in L-dopa treated PD patients 
compared with controls, but similar results were not found in drug naïve patients.137 
Plasma concentration correlates with disease severity and patients with high 
concentrations have  increased risk of hip fractures (RR = 2.42; 95%CI 1.21-3.63).138 
The underlying mechanisms causing hyperhomocysteinaemia in PD patients are not 
understood, however L-dopa therapy and possibly vitamin B12 and folate deficiency 
may be involved.136 137  
 
Therapeutic implications 
Despite the substantial fracture risk associated with PD, bone health assessment 
and management have been largely ignored and no clinical guidelines address this 
issue specifically in PD patients. Taking into account these limitations, several 
recommendations can be made (Figure 3).  
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- Fracture risk estimation: Fracture risk assessment tool (FRAX) and Qfracture 
are useful tools to estimate fracture risk and guide those who should undergo 
dual X-ray absorptiometry (DEXA) for a more accurate evaluation of bone 
mineral density. FRAX assessment might be slightly superior in assessing PD 
patients in the neurology clinic.139   
- Bisphosphonates: Until evidence exists to support PD patients having  
different DEXA thresholds for anti-osteoporotic therapy, it seems reasonable 
to apply general population recommendations regarding treatment with 
bisphosphonates.140 Both risedronate and alendronate have demonstrated an 
improvement of bone mineral density and reduction of hip fractures in 
patients with PD.141-143  
- Vitamin D: Levels should be routinely measured in PD patients and replaced 
if deficient. Vitamin D supplementation144 and increased sunlight exposure145 
have both demonstrated an amelioration of hypovitaminosis D, an increase in 
bone mineral density levels and a reduction in the fracture risk for PD 
patients.  
- Non-pharmacological therapies: An integrated approach including non-
pharmacological therapies such as exercise and lifestyle modifications should 
be included as part of a holistic care of PD.  
 
Key points 
 Patients with PD have an increased risk of fractures and reduced bone 
mineral density. 
 In addition to factors inherent to the disease increasing the risk of falls, there 
is a disruption of bone metabolism including vitamin D deficiency and 
hyperhomocysteinaemia. 
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 Routine bone health assessment and estimation of fracture risk is 
recommended with consideration of vitamin D supplementation if deficient, 
non-pharmacological therapies and treatment with bisphosphonates if 
indicated.  
 
CONCLUSION    
Metabolic and neuroendocrine abnormalities are common in PD and have important 
clinical implications. Clinicians should be aware of these abnormalities and include 
their assessment as part of routine clinical practice. Recognition and treatment of 
neuroendocrine and metabolic disturbances will intuitively improve PD care and 
patients’ quality of life. The underlying pathophysiology of these disturbances 
warrants further research. A better understanding of their pathogenesis may lead to 
accurate peripheral biomarkers of these abnormalities, which in turn may enable the 
development of more effective targeted therapeutic interventions and neuroprotective 
drugs. 
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FIGURE LEGENDS 
Figure 1. Circadian system and its dysregulation in Parkinson’s disease. 
The SCN of the hypothalamus is the central pacemaker and its rhythmic activity is 
the result of the expression of clock genes. The SCN receives photic information 
from the retino-hypothalamic tract, cues from peripheral oscillators and circulating 
melatonin. It also regulates melatonin secretion via an indirect multi-synaptic 
pathway reaching the pineal gland via the paraventricular nucleus of the 
hypothalamus and the superior cervical ganglion.  
Main disruptions found in PD are shown in shaded boxes.  
AUC, area under the curve; PVN, paraventricular nucleus; RHT, retino-hypothalamic 
tract; SCG, superior cervical ganglion; SCN, suprachiasmatic nucleus. 
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Figure 2. Feeding behaviour regulatory mechanisms and their dysregulation in 
Parkinson’s disease.  
Feeding behaviour is regulated by complex interactions between homeostatic and 
hedonic mechanisms. The hypothalamus is the central component of the 
homeostatic control and regulates the anorexigenic and orexigenic activity of its 
neurons using the information from peripheral signals.   
Main disruptions found in PD are shown in shaded boxes. Orexigenic areas are 
represented in hatched ovals and anorexigenic areas in white ovals. 
AgRP, agouti-related protein; CART, cocaine- and amphetamine-regulated transcript; 
CCK, cholecystokinin; DBS, deep brain stimulation; INF, infundibular nucleus; LHA, 
lateral hypothalamic area; MCH, melanin-concentrating hormone; MSH, melanocyte-
stimulating hormone; NA, nucleus accumbens; NPY, neuropeptide Y; OXM, 
oxyntomodulin; VTA, ventral tegmental area.  
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Figure 3. Bone health assessment and management in PD patients. 
Factors influencing fracture risk in PD patients and proposed assessment and 
management recommendations (see text).  
DEXA, dual X-ray absorptiometry; FRAX, fracture risk assessment tool; OT, 
occupational therapy; PD, Parkinson’s disease.  
 
